Since 2010, the number of clinical trials per year that rely on the action of perinatal cells unique to cord blood has been between 10 and 20 trials per year, averaging 14 trials per year. Note that this does not include standard hematopoietic stem cell transplantation trials because they do not meet our criteria of only archiving advanced cell therapy. Meanwhile, the number of clinical trials that rely on cells from other perinatal sources doubled over the 5 years from 2013 to 2017, from 28 to 56. The majority of this growth, averaging 84% of the other perinatal trials since 2010, is from clinical trials that rely solely on mesenchymal stem/stromal cells (MSCs) from any perinatal sources, including cord blood, cord tissue and the placenta.
You may also be interested in...
Cell therapy weekly: ISCT warns against unproven T-cell cryopreservation attempts
Cell therapy weekly: First FDA-monitored clinical trial for the use of stem cells in hypoplastic left heart syndrome patients
Member Exclusive NEWS ROUND-UP
Latest news & views, Cell therapy, Clinical trials, Industry developments, Manufacturing & scale-up, Basic research, Cord blood, MSCs
Cell therapy weekly: First-of-its kind iPSC-derived CAR-T cell therapy prepared for clinical testing